1. Introduction {#s0005}
===============

Schizophrenia (SZ) is a severe mental illness with high heritability, as well as structural and functional brain impairments. Genome wide association studies (GWAS) from Psychiatric Genomics Consortium (PGC) have announced landmark findings ([@bb0240]), which highlighted a list of susceptible loci. The disease-related abnormalities in brain regions were also demonstrated by many previous studies. For instance, gray matter (GM) volumes of the temporal and prefrontal gyrus were largely reported to be impaired ([@bb0020]; [@bb0170]; [@bb0265]). Functional connectivity (FC) computed from functional magnetic resonance imaging (MRI) data, which measures interregional temporal correlations of blood oxygenation level-dependent (BOLD) signal fluctuations, has been reported disabilities involving a number of brain regions, including the frontal lobe, sensory-motor areas, limbic structures and temporal gyrus([@bb0120]; [@bb0200]; [@bb0295]).

As different modalities may be related to each other constituting complementary observations of the same phenomenon, many multimodal methods have been developed and applied into analysis of mental disease ([@bb0040]; [@bb0155]; [@bb0165]; [@bb0195]; [@bb0250]). For example, Sui et al. developed a multimodal canonical correlation analysis plus joint independent component analysis (mCCA+jICA) method to reveal that GM density abnormalities in default model network (DMN) were related to white-matter impairments in anterior thalamic radiation in schizophrenia ([@bb0255]). Chen et al. used a parallel independent component analysis (para-ICA) method to reveal that higher activation in precentral and postcentral gyri was observed in SZ with higher loadings of the linked SNP component ([@bb0040]). Nervertheless, there are few studies combining structural, functional and genomic data to analyze schizophrenia.

Moreover, it\'s still not clear whether there are progressive changes in each modality and the time at which for changes in different modalities are first evident. Previous studies have explored the progressive changes primarily based on single modality. For example, the progressive decreases of GM volumes were pronounced mainy in the temporal and prefrontal gyrus, while increase in the lateral ventricle ([@bb0105]). Another recent study consisting of 39 medication naïve, first-episode schizophrenia and 31 matched controls revealed that first-episode patients presented reduced global efficiency and decreased regional nodal efficiency in hippocampal and precuneus ([@bb0190]). Li et al. demonstrated that 90% of the FC changes during the first-episode stage of SZ were centered on the inferior frontal gyrus, while more thalamus-related connectivity were extended to show FC differences in chronic SZ patients ([@bb0140]). However, the direct comparison of progressive impairments among different modalities are not largely explored. Based on the linked SNP-FC-GM pattern identified from the multimodal fusion method, we can further compare the modality-specific sensitivity to the disease progression.

Overall, in this study, we performed a multimodal analysis ([@bb0300]) of first-episode SZ patients (FESZ), chronic SZ patients (CSZ) and healthy controls (HC) with three features, i.e., GM volume, FC and single nucleotide polymorphisms (SNP), aiming to evaluate the links among the three modalities, and their association with duration of illness (DOI) and disease stages. Note that we preselected SNPs from PGC\'s SCZ2 database based on the *p*-value, while these SNPs are not functionally homogeneous. Since our recent study has proved that no reliable SNP-imaging association was noted in the polygenic risk score (PGRS) analyses when calculating PGRS on SNPs with high heterogeneity ([@bb0045]). The multimodal data-driven method would slove this by computing subgroups of all SNPs first and then inverstigate the associated structural and functional brain impairments based on the subgroups. These subgroup SNPs are more likely to converge within brain regions. We hypothesized that a significant correlated SNP-FC-GM pattern would be revealed, as well as significant group differences among HC, FESZ and CSZ in each modality. More importantly, different sensitivity to DOI and disease stages (i.e., the order of feature impairment) would be revealed for different modalities, which may provide us additional clues regarding the impact of mental illness at various disease stages.

2. Materials and methods {#s0010}
========================

2.1. Participants {#s0015}
-----------------

159 subjects were recruited from Wuxi Mental Health Center, consisting of eighty-seven HC, twenty drug-naïve FESZs and fifty-two CSZs. [Table 1](#t0005){ref-type="table"} describes the demographic information of the data. Patients who have DOI ≤ 2 years were definded as FESZ patients (0.96 ± 0.85), others were identified as chronic patients (20.63 ± 9.84). Subjects were excluded if they had any current or past neurological illness, substance abuse or head injury resulting in loss of consciousness. All the patients were diagnosed according to the DSM-IV diagnostic criteria by at least two qualified psychiatrists.Table 1Demographic characteristics of the subjects in the present study.Table 1DemographicsHCFESZCSZ*p*Number872052GenderM/F47/4010/1030/220.83Age (y)Mean ± SD39.91 ± 14.8433.60 ± 10.8046.12 ± 11.380.0011EducationMean ± SD12.67 ± 4.2810.65 ± 4.6510.75 ± 2.690.0091Duration of Illness (y)Mean ± SDNA0.96 ± 0.8520.63 ± 9.84Chlorpromazine EquivalentMean ± SDNADrug-naïve17.26 ± 9.44PANSS positiveMean ± SDNA27.8 ± 4.6419.62 ± 3.829.20E-08PANSS negativeMean ± SDNA19.65 ± 4.7824.40 ± 3.523.87E-04PANSS generalMean ± SDNA46.45 ± 7.4941.77 ± 5.110.016[^2]

2.2. Data collection {#s0020}
--------------------

All subjects were scanned by structural MRI and resting-state functional MRI on a 3.0-Tesla Magnetom TIM Trio (Siemens Medical System) at the Department of Medical Imaging, Wuxi People\'s Hospital, Nanjing Medical University. Foam pads were used to reduce head motion and scanner noise. Prior to the scan, the subjects were instructed to keep their eyes closed, relax but not fall asleep, and move as little as possible during data acquisition. **fMRI:** Resting-state scans were acquired using a single-shot gradient-echo echo-planar-imaging sequence as ([@bb0285]) with the following parameters: TR = 2000 ms, TE = 30 ms, flip angle = 90°, matrix size = 64 × 64, FOV = 220 × 220 mm^2^, 33 axial slices, slice thickness = 4 mm, acquisition voxel size = 3.4 × 3.4 × 4 mm^3^, resulting in 240 volumes. **sMRI:** Three-dimensional T1-weighted images were acquired by employing a 3D-MPRAGE sequence as ([@bb0285]) with the following parameters: time repetition (TR) = 2530 ms, time echo (TE) = 3.44 ms, flip angle = 7°, matrix size = 256 × 256, field of view (FOV) = 256 × 256 mm^2^, 192 sagittal slices, slice thickness = 1 mm, acquisition voxel size = 1 × 1 × 1 mm^3^, total acquisition time = 649 s.

All participants provided blood samples for genetic analysis. Genomic deoxyribonucleic acid (DNA) was extracted according to the standard protocol by protease K digestion, phenol-chloroform extraction and ethanol precipitation. Afterwards, whole-genome genotyping was conducted on 571,054 loci using Illumina human PsychArray-24.

2.3. Data preprocessing {#s0025}
-----------------------

The structural MRI data and functional MRI data were preprocessed using the SPM8 ([www.fil.ion.ucl.ac.uk/spm/software/spm8](http://www.fil.ion.ucl.ac.uk/spm/software/spm8){#ir0005}) voxel based morphometry module and the Brant software (<http://brant.brainnetome.org/en/latest/>, [@bb9066]), respectively (see supplementary file for more details). A mask for the preprocessed structural data was then generated to include voxels with a mean value larger than 0.2 across all the subjects ([@bb0260]). Based on the 116 × 116 automatic anatomical labelling (AAL) atlas, FC network was constructed upon computing pearson correlation of averaged BOLD signals between all pairs of regions, resulting in 6786 edges. The genetic data were preprocessed using PLINK following the quality control procedures in ([@bb0010]; [@bb0225]) and further overlaped with PGC\'s SCZ2 database (*p* \< 0.01), resulting in 4937 SNPs (see supplementary file). Discrete numbers were assigned to the categorical genotypes: 0 for no minor allele, 1 for one minor allele, and 2 for two minor alleles.

Accordingly, the three feature matrices included: FC (subjects by voxels: 159 × 6786), GM (subjects by voxels: 159 × 77,122) and SNPs (subjects by alleles:159 × 4937). The feature matrices were then normalized to ensure that all modalities had the same average sum-of-squares (computed across all subjects and all voxels/SNPs for each modality). Medication information (chlorpromazine equivalent) was regressed out for the chronic patients prior to additional analyses.

2.4. Data analysis {#s0030}
------------------

### 2.4.1. Three-way para-ICA {#s0035}

We firstly applied three-way para-ICA to identify a linked SNP-FC-GM pattern as shown in [Fig. 1](#f0005){ref-type="fig"}. Three-way para-ICA is a multivariate association analysis method that estimates maximally independent components within each modality using Infomax ICA separately and maximizes the sum of pair-wise correlations between modalities (Method details are provided in the supplementary file) ([@bb0175]; [@bb0300]). The code is open through the Fusion ICA Toolbox (FIT, <http://mialab.mrn.org/software/fit>). The number of components was measured to be 14 for FC and GM modalitites through a modified minimum description length (MDL) criterion ([@bb0135]), an efficient method as discussed in previous ICA associated studies ([@bb0030]; [@bb0025]; [@bb0065]). A consistency-based method was used to identify number of components for the SNP modality ([@bb0040]), which ran ICA decompositions across a range of numbers of components and determined the comoponent number with the most reliable results (in our case the final model order was estimated to be 6).Fig. 1Analysis pipeline of the study. We firstly applied three-way para-ICA on the healthy controls (HC), first-episode schizophrenia (FESZ) and chronic schizophrenia (CSZ) subjects with three modalities \[Single nucleotide polymorphism (SNP), functional connectivity (FC) and gray matter (GM)\] to identify a linked SNP-FC-GM pattern. Afterwards, ANOVA analysis and two sample *t*-test were used to measure the group difference across groups for the linked SNP-FC-GM pattern. We further plotted the relationship between the identified imaging modalities and duration of illness (DOI), and used the slopes to compare sensitivity for FC and GM.Fig. 1

### 2.4.2. Correlation and group difference analysis {#s0040}

Cross correlations among the loading parameters of the three modalities were assessed, and the significant levels were adjusted using Bonferroni correction for multiple comparison. To measure the consistency of the identified joint pattern across participants, we applied a ten-fold cross validation method to replicate the associations ([@bb0040]). Moreover, in order to evaluate the stability of the linked SNP-FC-GM pattern, we conducted 1000 permutation tests to investigate the possibility of overfitting. Particularly, we randomly permuted subjects of all the three modalities and ran three-way para-ICA again on the permuted subjects. Then we extracted the top correlated SNP-FC-GM pair in each of the 1000 permutation tests and calculated the tail probability to evaluate the significance level of the identified SNP-FC-GM association. Finally, the sptial maps of the SNP-FC-SNP pattern were transformed to Z scores and the top contributing brain regions, FC and SNPs were selected and plotted.

### 2.4.3. Sensitivity to disease stages and DOI {#s0045}

To investigate the different sensitivities to diease stages and DOI, we applied analysis of variance (ANOVA) analysis and two sample *t*-test to measure the group difference across different disease stages within each modality for the linked SNP-FC-GM pattern ([Fig. 1](#f0005){ref-type="fig"}). Then we calculated the relationship between the identified imaging modalities and DOI, and used Z value to compare the difference between slopes of the two modalities. Specifically, we first applied generalized linear regression (GLM) model to identify a regression line for the relationship between imaging modalitites and DOI. Then the slope of the regression line was the corresponding beta value of the loading parameter of each modality (*k*~*GM*~ for the GM modality and *k*~*FC*~ for the FC modality). Z value was computed as the difference between the two slopes divided by the standard error of the difference between the slopes. As the GLM model gave us the standard error of each slope (*stand*\_*k*~*GM*~ for the GM modality and *stand*\_*k*~*FC*~ for the FC modality), then the standard error of the difference between the two slopes can be computed as $\sqrt{\mathit{stand}\text{\_}{k_{\mathit{GM}}}^{2} + \mathit{stand}\text{\_}{k_{\mathit{FC}}}^{2}}$. Then we calculated the Z value as Eq. [(1)](#fo0005){ref-type="disp-formula"}:$$Z = \frac{k_{\mathit{GM}} - k_{\mathit{FC}}}{\sqrt{\mathit{stand}\_{k_{\mathit{GM}}}^{2} + \mathit{stand}\_{k_{\mathit{FC}}}^{2}}}$$

Afterwards, we computed the two-tailed *p*-value corresponding to the Z value to evaluate the significance of the two slopes.

### 2.4.4. Genetic pathway analysis {#s0050}

After converting the spatial map of the SNP component to Z scores, the high-ranking SNPs (\|Z\| \> 2) were annotated to genes. To further interpret the relationship between the SNP component and schizophrenia, we fed these top contributing genes to the WebGestalt software for Gene Ontology (GO) analysis ([@bb0305]), which used a hypergenometrix test to detect overrepresentation of the genes among the whole genome in a GO category.

3. Results {#s0055}
==========

3.1. SNP-FC-GM multivariate linkage {#s0060}
-----------------------------------

The strongest connected SNP-FC-GM triplet from the three-way para-ICA was identified, which presented significant pair-wise correlations (FC-GM: *r* = 0.58, *p* \< 10^−12^; SNP-FC: *r* = 0.31, *p* = 8.83 × 10^−5^; SNP-GM: *r* = 0.32, *p* = 3.39 × 10^−5^, passing the Bonferroni correction) as shown in [Fig. 2](#f0010){ref-type="fig"}A. Ten-fold analysis revealed that the correlations were stable with averge correlation of 0.58 ± 0.08(FC-GM), 0.28±0.04(SNP-FC), 0.27±0.06(SNP-GM). Permutation tests further indicated the significance of the links with empirical *p*-values of 0.001(FC-GM), 0.03(SNP-FC), 0.01(SNP-GM).Fig. 2The pairwise correlation plots of the identified SNP-FC-GM component. (A) The correlation among FC, GM and SNP modalities before regressing out any variables. (B) The correlation among FC, GM and SNP modalities after regressing out age, gender, education and diagnosis. Note: The blue dots represent the healthy controls(HC). The red dots represent the chronic schizophrenia patients (CSZ). The green dots represent the first-episode schizophrenia patients(FESZ).Fig. 2

Partial correlations of the linked SNP-FC-GM pattern were still significant when controlling for diagnosis, age, education and gender (SNP-FC: *r* = 0.21, *p* = 0.0074; SNP-GM: *r* = 0.27, *p* = 6.27 × 10^−4^, FC-GM: *r* = 0.19, *p* = 0.015) as shown in [Fig. 2](#f0010){ref-type="fig"}B, passing Bonferroni correction. The positive correlations of SNP-FC and SNP-GM indicated that higher allele counts for the positively contributing SNPs were associated with an increase of both FC and GM; higher allele counts for the negatively contributing SNPs were associated with a decrease of both FC and GM. The positive correlations between FC and GM revealed that FC decrease was related with GM volume reduction.

3.2. Different sensitivity to disease stages and DOI {#s0065}
----------------------------------------------------

Group differences across HC, FESZ and CSZ measured by ANOVA in FC (*p* = 6.09 × 10^−49^), GM(*p* = 2.82 × 10^−15^) and SNP(*p* = 0.0024) were significant. [Fig. 3](#f0015){ref-type="fig"}A further despicts the results of two sample *t*-test comparison between groups within each modality. Both FC and GM displayed evidence of greater deficits at late disease stage compare to healthy controls and early stage (HC \> FESZ\>CSZ). Notably, significant group differences were observed in all pairs for the FC component (HC-FESZ: *p* = 2.26 × 10^−6^, HC-CSZ: *p* \< 1 × 10^--10,^ FESZ-CSZ: *p* = 2.05 × 10^−8^), while the GM component only presented obvious significance in HC-CSZ (*p* \< 1 × 10^−10^) and FESZ-CSZ (*p* = 5.34 × 10^−7^). Compared to the imaging modalities, no significant group difference between FESZ and CSZ in the SNP component was revealed, but group difference between HC and FESZ (*p* = 0.0023), or HC and CSZ (*p* = 0.0083) was significant.Fig. 3Different sensitivity to disease stages and DOI. (A) ANOVA and two-sample *t*-tests within each modality. Note: The *p*-values display results of ANOVA analysis. The red violin plot represents healthy controls (HC). The green violin plot represents first-episode schizophrenia patients (FESZ). The blue violin plot represents the chronic schizophrenia patients (CSZ). \*represent 0.00001 \< *p* \< 0.05, \*\* represents 1e-5 \< p \< 1e-10, \*\*represents p \< 1e-10. (B)Different sensitivity comparison between the GM and FC modality to DOI. Note: the gray and black dots represent correlation between GM, FC loadings and DOI respectively. The gray and black regression lines represent the slope of the correlation. The two-tailed *p*-value of the z values between two slopes is significant (*p* = 0.00063).Fig. 3

Moreover, [Fig. 3](#f0015){ref-type="fig"}B displays the relationship between imaging loadings and DOI. FC (*k* = −0.0036) presented a sharper slope than GM (*k* = −0.0006), which means FC deteriorates faster than GM with the same DOI. The z-value of the two slopes was −3.42 with a corresponding two-tailed p-value as 0.00063, which indicated that FC presented a stronger negative correlation with DOI than GM.

3.3. The linked imaging modalities {#s0070}
----------------------------------

As shown in [Fig. 4](#f0020){ref-type="fig"}, the GM component and FC component were converted into Z scores and displayed at \|Z\| \> 2.5. Since the components have been adjusted as HC \> SZ on the mean of loading parameters as shown in [Fig. 3](#f0015){ref-type="fig"}, the red regions/connections in [Fig. 4](#f0020){ref-type="fig"} indicated higher contribution in HC than SZ, and the blue regions/connections indicated higher contribution in SZ than HC ([@bb0260]). Accordingly, GM decrease in patients centered on amygdala, temporal gyrus, parahippocampal gyrus, postcentral gyrus, and increase in inferior parietal gyrus and cerebellum as shown in [Fig. 4](#f0020){ref-type="fig"}A. The detailed anatomical information of the abnormal brain regions are listed in Table S2. As shown in [Fig. 4](#f0020){ref-type="fig"}B, SZ patients present lower FC primarily in amygdala, postcentral, hippocampus/parahippocampus, temporal gyrus, and higher FC primarily in cerebellare and inferior parietal related connectivity.Fig. 4The abnormal brain regions and functional connectivity revealed by three-way para-ICA. (A) Brain regions showing gray matter abnormalities in the SNP-FC-GM pattern. The red regions represent gray matter decrease in SZ while the blue regions represent gray matter increase in SZ. (B) Imparied FC identified from the SNP-FC-GM pattern. The red connecting lines represent FC decrease in SZ, while the blue connecting lines represent FC increase in SZ.Fig. 4

3.4. The joint SNP component and pathway analysis {#s0075}
-------------------------------------------------

Similarly, the SNP component was also transformed to Z scores and visualized at \|Z\| \> 2, which highlighted 258 risk SNPs as listed in Table S2. [Fig. 5](#f0025){ref-type="fig"}A displays a Manhattan plot for the SNP component. After annotating the 258 high-ranking SNPs, 101 genes were revealed, including *SATB2*, *GABBR2*, *PDE4B* and *CACNA1C* et al. [Fig. 5](#f0025){ref-type="fig"}B depicts the significant GO results, including cell junction, perinuclear region of cytoplasm, neuron part, synapse, postsynapse, neuron projection, plasma membrane receptor complex, postsynaptic density and postsynaptic specialization. Note that the p-vlaues shown in [Fig. 5](#f0025){ref-type="fig"}B were all FDR corrected. The included genes for each GO function are listed in Table S3.Fig. 5Mahattan plot and GO analysis of the joint SNP component. (A) Manhattan plot of the identified SNP component. (B) GO analysis results of the high-ranking SNP with \|*Z*-scores\| \> 2; *P*-values are all FDR corrected.Fig. 5

4. Discussion {#s0080}
=============

This study first jointly analyzed correlation between FC, GM volume and SNP in schizophrenia and further evaluated the different sensitivity to DOI and disease stages for imaging modalities. Results revealed a linked SNP-FC-GM pattern, with significant group differences among HC, FESZ and CSZ of each modality. Impairments of GM and FC were centered on hippocampal, temporal gyrus and cerebellum in schizophrenia. These changes were further significantly associated with SNPs residing in genes like *SATB2*, *GABBR2*, *PDE4B* and *CACNA1C* et al.*,* involved in pathways of cell junction formation, and synapse and neuron projection. Moreover, post-hoc analysis revealed that both GM and FC presented greater deficits at later disease stages (HC \> FESZ\>CSZ), and FC presented a stronger negative correlation with DOI than GM.

4.1. Linked SNP-FC-GM pattern {#s0085}
-----------------------------

We first identified the most significantly correlated SNP-FC-GM pattern using three-way para-ICA, which passed the significant levels after Bonferroni correction for multiple comparisons. Then partial correlation on the identified SNP-FC-GM pattern (using diagnosis, age, education and gender as covariates) revealed a weak but still significant correlation among the three modalities. We found decreased GM volume in the temporal gyrus, parahippocampal gyrus, postcentral gyrus and amygdala-hippocampus complex, consistent with the previous studies in ([@bb0090]; [@bb0310]; [@bb0320]), coaltered with the low FC strength in prefrontal, temporal, hippocampus/parahippocampus and amygdala ([@bb0130]; [@bb0160]; [@bb0330]). Increased GM were revealed mainly in cerebellum and inferior parietal lobule([@bb0235]; [@bb0270]) in patients, as well as increased FC in these two brain regions([@bb0005]; [@bb0295]). Shared impaired brain regions between GM and FC modalities focused on hippocampus, temporal gyrus, cerebellum and parietal gyrus. The decreased GM volumes of temporal gyrus are implicated for the impairment in sensory integration, storage of language and voice information, and higher-order cognitive functions ([@bb0220]). Amygdala and hippocampus are critical for memory functions and affect perception([@bb0320]). The parahippocampal gyrus is part of the medial temporal lobe, which receives input from heteromodal association areas of the cortex and projects into the limbic circuit for information transmission ([@bb0180]). The cerebellum has been revealed to primarily coordinate motor activity for years and viewed as a key cognitive region in the brain which is impaired in schizophrenia by the previous study([@bb0015]). The parietal lobe is important in processes of language, attention and spatial working memory, which are likely to be disturbed in schizophrenia ([@bb0275]).

The joint SNP component primarily highlighted SZ-susceptible genes including *PDE4B*, *EGF*, *SATB2*, *PPP1R16B*, *GABBR2* and *CACNA1C etc.*, which have been reported to be significantly associated with schizophrenia in previous studies. For example, *PDE4B* interacts with *DISC1* to regulate cAMP signaling, which is impared in schizophrenia ([@bb0205]). Patients with mutations or deletions within the *SATB2* locus exhibit severe learning difficulties and profound mental retardation ([@bb0150]). Devor et al. has found PP1 subunits including *PPP1R16B* plays a central role in the integration of fast and slow neurotransmission([@bb0060]). The *CACNA1C* is also revealed as a SZ-susceptible gene in ([@bb0095]). Further GO analysis of the annotated top contributing genes revealed a significant enrichment of cell junction, synapse and neuron projection. Consistently, reduced neuron projection of schizophrenia patients in the hippocampus and thalamocortex has also been revealed in previous studies ([@bb0055]; [@bb0100]). Synapse primarily participates in the information transmission process ([@bb0085]). Impairment of synaptic transmission during childhood and adolescence would lead to altered synapse formation or pruning ([@bb0210]). Moreover, the SNP component was significantly correlated with the imaging impairments, supported by previous studies. For example, GABBR1 and GABBR2 were revealed to be altered significantly in the lateral cerebellum of SZ patients ([@bb0280]). *SATB2* has been reported to control the hippocampal levels of a large cohort of miRNAs, many of which are implicated in synaptic plastic and memory formation([@bb0110]). The *CACNA1C* gene is widely expressed in the entire nervous system, especially the thalamus and hippocampus areas ([@bb0215]). Decreased expression of *PDE4B* has been observed in the tissues of Brodmann\'s area 6 of frontal cortex and cerebellum([@bb0080]).

4.2. Different sensitivity to disease stage and DOI {#s0090}
---------------------------------------------------

Post-hoc 2-sample *t*-test revealed that GM impairments in FESZ were not significant compared to HC, while CSZ exhibited significant group difference compared to both FESZ and HC. Unlike GM, FC presented significant group difference between FESZ and HC, and a larger impairment in CSZ. We have noticed that there were some literatures in schizophrenia stating that notable GM and FC deficits were revealed in the early stage of the disease. However, in current work, we only observed moderately decreased GM in FESZ, due to the following potential reasons.1) The first-episode patients collected in current study have a relatively short duration of illness (≤ 2 years), less than those FESZ reported with DOI≤5 years, and previous studies ([@bb0115]; [@bb0125]; [@bb0315]) also reported un-significant GMV reduction in the high-risking patients and progressive GMV reductions in schizophrenia patients, supporting our findings. 2) Earlier age of onset of schizophrenia has been reported to be associated with larger regional GM deficits([@bb0290]) and worse outcome([@bb0050]). In this study, the FESZ patients are primarily middle-aged adults (33.60 ± 10.80 years old) rather than adolescents, which may infer less GM impairments in the patients compared to other studies. 3) We only focused on the subgroups of the GM and FC data which were simultaneously related with the SNP cluster. For example, lower gray matter volumes in FESZ reported in previous studies were mostly found in the anterior cingulate, insula, caudate and putamen ([@bb0075]; [@bb0230]). While in this study, the peak regions were observed in the amygdala, temporal pole, parahippocampal gyrus, postcentral gyrus, primarily reported in chronic patients ([@bb0035]; [@bb0245]), which may lead to the un-significant group difference in FESZ.

Notably, these impaired regions were also identified in the FC component, which presented significant group difference between FESZ and HC. Previous studies supported this by reporting abnormalities in these regions at first-episode stages, for example the middle temporal gyrus ([@bb0130]; [@bb0140]; [@bb0325]) and parahippocampus areas ([@bb0070]; [@bb0185]). Accordingly, we suggested that functional connectivity presented a greater gradient of decline to duration of illness than GMV in specific brain regions at the early stage of the disease, including the parahippocampus, inferior temporal gyrus and postcentral gyrus. More importantly, even though these results are statistically significant, further validation based on longitude subjects and larger dataset were also awaited.

A limitation in this study is that all the chronic patients received medication, and even though we have regressed out the medication effect before conducting analysis, the differences between FESZ and chronic patients could still be influenced by the antipsychotic medication and/or symptom severity. A second limitation is that our sample size, especially FESZ, is relatively small and the absence of a replication dataset with all 3 modalities; however, these findings still provide important clues for the study of schizophrenia progression. Another limitation is that we preselected the risk SNPs based on the PGC\'s GWAS results rather than Chinese Han GWAS study. However, Li et al. has recently demonstrated that the top risk loci from PGC\'s GWAS are largely consistent between the two populations([@bb0145]), which provide support for our preselecting SNPs from PGC and analyzing them on the Chinese Han dataset. Future work should validate the results using Chinese GWAS results when the summary data of the Chinese GWAS study is available to the public.

5. Conclusions {#s0095}
==============

To the best of our knowledge, this study is the first attempt to evaluate the associations between the SNP-FC-GM patterns in schizophrenia and compare the sensitivity to DOI and disease stages for imaging modalities. Results suggested that: 1) GM volume impairments and FC abnormalities in hippocampus, temporal gyrus, parietal and cerebellum are revealed in schizophrenia, which were associated with genetic factors e.g.*, SATB2*, *GABBR2*, *PDE4B*, *CACNA1C etc*. 2) GM and FC showed evidence of greater deficits at later disease stages (HC \> FESZ\>CSZ), while SNP indicated a non-gradual variation trend with un-significant group difference observed between FESZ and CSZ; 3) Group difference between HC and FESZ of FC was more obvious than GM, and FC presented a stronger negative correlation with DOI than GM. Collectively, these results deep our understandings of impaired SNP-FC-GM correlation towards schizophrenia and provide important clues regarding the impact of mental illness at various disease stages.
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